A novel strategy, targeting glycolytic system for radiation resistant head and neck cancer
| Project/Area Number |
15H06379
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
Junji Miyabe 大阪大学, 医学部附属病院, 医員 (60756831)
|
|---|
| Project Period (FY) |
2015-08-28 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 頭頸部癌 / 放射線抵抗性 / 解糖系 / MCT4 / 放射線抵抗性頭頸部癌 / トランスポーター |
|---|
| Outline of Final Research Achievements |
Monocarboxylate transporter 4 (MCT4) is a transporter of lactate. I confirmed the expression of MCT4 in head and neck cancer cell lines (Fadu, Detroit562, BICR6). I used small-interfering RNA to silence its expression. I demonstrated that knock-down of MCT4 decreased cell proliferation. Hypoxic condition induced the cell proliferation in Fadu cell line. Knock-down of MCT4 suppressed the cell proliferation in hypoxic condition.
It is reported that hypoxia induces radioresistance. These results suggest that knock down of MCT4 may suppress the cell proliferation of hypoxia-induced radioresistant cancer.
|
Report
(3 results)
Research Products
(1 results)
